Overview

Low Dose Naltrexone for Glioma Patients

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation

Phase:

Phase 2

Details

Lead Sponsor:

Katy Peters

Treatments:

Naltrexone